Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

globenewswire.com - Pharma Equity Group A/S - Pharma Equity Group A/S - Annual Report 2025
Pharma Equity Group A/S - Annual Report 2025
GlobeNewswire

Pharma Equity Group A/S - Annual Report 2025 Pharma Equity Group A/S - Annual Report 2025 – Highlights of the year Today, the Board of Directors of Pharma Equity Group A/S reviewed and approved the Company's Annual Report for 2025, the key…

globenewswire.com - Pharma Equity Group A/S - Notice convening the annual general meeting in Pharma Equity Group A/S
Notice convening the annual general meeting in Pharma Equity Group A/S
GlobeNewswire

Notice convening the annual general meeting in Pharma Equity Group A/S The board of directors hereby convenes the annual general meeting in Pharma Equity Group A/S (“PEG” or the “Company”) to be held on: The agenda for…

prnewswire.com - Piramal Pharma Solutions - Piramal Pharma Solutions Commemorates 20th Anniversary at Morpeth Facility with Procurement of Korsch X3 Tablet Press
Piramal Pharma Solutions Commemorates 20th Anniversary at Morpeth Facility with Procurement of Korsch X3 Tablet Press
Cision PR Newswire

Morpeth recently commissioned a new Korsch XM12 Single Layer/Bilayer press, a smaller-scale model that laid the foundation for the site's commitment to the latest tablet press technology in the PreCommercial domain. As late phase and commercial…

seekingalpha.com - Edmund Ingham - Alumis: Oral Psoriasis Med Can Win Approval, Challenge Big Pharma In Major Markets (ALMS)
Alumis: Oral Psoriasis Med Can Win Approval, Challenge Big Pharma In Major Markets (ALMS)
Seeking Alpha

Alumis Inc. is upgraded to Buy, reversing a prior Sell, based on strong Phase 3 envudeucitinib psoriasis data and pipeline potential. Envudeucitinib demonstrated efficacy comparable to JNJ's newly approved Icotyde, with 74% PASI 75 and 59% sPGA 0/1…

thehindu.com - The Hindu Bureau - Aurobindo Pharma arm ties up with European firm for biosimilars
Aurobindo Pharma arm ties up with European firm for biosimilars
The Hindu

Aurobindo Pharma subsidiary CuraTeQ Biologics has entered into a marketing and distribution agreement with European healthcare and pharmaceuticals company STADA Arzneimittel AG for two biosimilars. Under the agreement, STADA will market and…

politico.eu - Sophie Inge - UK-Swiss trade deal held up over pharma row
UK-Swiss trade deal held up over pharma row
POLITICO

At the center of the disagreement is something called a Supplementary Protection Certificate (SPC). The U.K., Switzerland and the EU all operate SPC regimes, which extend patent protection for pharmaceuticals beyond the standard 20-year term. Swiss…

law360.com - Brian Malkin and John Allen - New Orphan Drug Law Provides A Key Fix For Pharma Cos.
New Orphan Drug Law Provides A Key Fix For Pharma Cos.
Law360

In early February, Congress enacted the 2026 Consolidated Appropriations Act, delivering a significant legislative fix for the pharmaceutical industry.[1]... To view the full article, register now. Already a subscriber? Click here to view full…

marketbeat.com - Insider Selling: Royalty Pharma (NASDAQ:RPRX) CFO Sells 34,791 Shares of Stock
Insider Selling: Royalty Pharma (NASDAQ:RPRX) CFO Sells 34,791 Shares of Stock
MarketBeat

Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report) CFO Terrance Coyne sold 34,791 shares of the stock in a transaction dated Monday, March 23rd. The stock was sold at an average price of $45.53, for a total transaction of $1,584,034.23. Following…

marketbeat.com - Ascentage Pharma Group International (NASDAQ:AAPG) Shares Up 20.3% - Should You Buy?
Ascentage Pharma Group International (NASDAQ:AAPG) Shares Up 20.3% - Should You Buy?
MarketBeat

Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - Get Free Report)'s share price shot up 20.3% during trading on Wednesday. The stock traded as high as $23.00 and last traded at $22.9850. 202 shares traded hands during mid-day…

benzinga.com - Earnings Scheduled For March 25, 2026 - ATA Creativity Global (NASDAQ:AACG), Ascentage Pharma Group (NASDAQ:AAPG)
Earnings Scheduled For March 25, 2026 - ATA Creativity Global (NASDAQ:AACG), Ascentage Pharma Group (NASDAQ:AAPG)
Benzinga

• Chewy (NYSE:) is expected to report quarterly earnings at $0.20 per share on revenue of $3.26 billion. • Maze Therapeutics (NASDAQ:) is estimated to report earnings for its fourth quarter. • Winnebago Industries (NYSE:) is…

marketbeat.com - aTyr Pharma, Inc. (NASDAQ:ATYR) Given Average Recommendation of 'Hold' by Analysts
aTyr Pharma, Inc. (NASDAQ:ATYR) Given Average Recommendation of 'Hold' by Analysts
MarketBeat

aTyr Pharma, Inc. (NASDAQ:ATYR - Get Free Report) has been given a consensus recommendation of 'Hold' by the seven research firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a…

globenewswire.com - Boehringer Ingelheim Limited - Boehringer Ingelheim delivers on late-stage pipeline with two key launches, grows sales by 7.3%* in a successful 2025
Boehringer Ingelheim delivers on late-stage pipeline with two key launches, grows sales by 7.3%* in a successful 2025
GlobeNewswire

Intended audience: global business, financial and trade media HERNEXEOS (zongertinib) and JASCAYD (nerandomilast) launched in H2, 2025 Group net sales increased 7.3%* to EUR 27.8 billion in 2025 R&D investments grew to EUR 6.4 billion, equivalent…

bloomberg.com - Yasutaka Tamura - Japan Posts Longest Streak of First-Day IPO Flops Since 2020
Japan Posts Longest Streak of First-Day IPO Flops Since 2020
Bloomberg

Japan's run of struggling stock market debuts has stretched to the longest in six years, another sign of investor sentiment being shaken by the war in Iran. J-Pharma Co. dropped as much as 22% and Basic Inc. fell as much as 8% on their first day of…

fool.com - Motley Fool Transcribing - Paysign (PAYS) Q4 2025 Earnings Call Transcript
Paysign (PAYS) Q4 2025 Earnings Call Transcript
The Motley Fool

Tuesday, March 24, 2026 at 5 p.m. ET President & Chief Executive Officer — Mark Newcomer Chief Financial Officer — Jeffery Baker President, Patient Affordability — Matthew Turner Chief Payments Officer — Matt Lanford…

indianexpress.com - Sohini Ghosh - Why Dr Reddy's generic weight-loss drug under Olymviq brand won't hit markets till Friday
Why Dr Reddy's generic weight-loss drug under Olymviq brand won't hit markets till Friday
The Indian Express

4 min read New Delhi Make us preferred source on Google Several cheaper generics of semaglutide, the blockbuster weight-loss drug, launched in India this week, though Dr Reddy's Laboratories' (DRL) generic version, under the Olymviq brand, will not…

Receive a Daily briefing on Pharma Industry News

Get Started